Exogems SA, a pioneering Swiss biotech company developing innovative therapeutic exosomes derived from microfragmented adipose tissue, today announced the successful completion of a CHF 500K fundraising round from business angels. This significant investment will fuel the company’s mission to harness the potential of exosomes in treating inflammation, infection, and cancer.
Exogems’ pioneering approach leverages the unique properties of exosomes, which are tiny vesicles released by cells that can carry therapeutic molecules to specific targets within the body. By utilizing microfragmented adipose tissue as a source of exosomes, the company aims to create a new generation of treatments that are more eOective, safer, and more targeted than traditional therapies.
